Biomea Fusion, Inc. (BMEA)
NasdaqGS · USD · Healthcare · Biotechnology
$0.6356 (+5.92%) as of
Key statistics
- Market cap
- 45.95M
- Forward P/E
- -0.68
- EPS (TTM)
- -0.2900
- Dividend yield
- 0.00%
- 52-week range
- 0.5520 – 2.2370
- Beta
- -0.30
- Profit margin
- 0.00%
- Analyst target
- $6.17
- Volume
- 1.52M
About Biomea Fusion, Inc.
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- San Carlos, CA, United States
- Employees
- 37
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.